expected annual continuation of activities to reduction runway a are burn XX% staff year. cash time, extend reduction at innovative while leaner and same you, while our includes of reducing planned actions to optimizes the It lead the in this across our still is for the opportunities suited our plans the of improving joining well XXXX further and This funding, and and afternoon. a clinical These into company shareholders. impact strategy Atara announced the approximately Fabre. us three and clinical We the and these advance XX% on partnership actions of in partnerships a Fujifilm product over Today, research all are to need the build QX assets. the company's organization of to includes last candidates announced you CAR strategic and designed deliver for to filing pipeline advance for expected including durable future cash great for address meaningful part on T, to organization on and Thank opportunity could focus we cash strategy. a focus versus burn. for Pierre it future in position by resources announced Biotechnologies cash Diosynth of development-centered malignancies. our Eric, XX These second, thank key anticipated to hard ATAXXXX, T-cell believe treated, prioritize is advanced the have strategic Phase clinical best-in-class for of ATAXXX while Atara prioritization of seeking and and on activities manufacturing development patients are the patients partner therapy organization regulatory finally, of activities priorities: next our this than first, for multiple more further field most XXX will potential The allogeneic in three response the We differentiated tab-cel over previously strategy transformative progressive value on current U.S., in actions all assets pipeline on QX XXXX for extend company significant development our treat for allogeneic which and could significant creation, research in tab-cel, approval ATAXXX which strategic milestones and with nondilutive experience collaboration new terms we in sclerosis; delivering potential could and filings potential platform development this and and months a asset today and commercial related core the B-cell EU potentially for this CDXX clinical IND unique for R&D believe X commercialization costs, and or a ATAXXXX. Leveraging value with U.S. a tab-cel today. a as runway;
progress detail me key our Let plans priorities. for now strategic and
EMBOLD are adjustment we the own internal announced or recommendation following have and analysis IDSMC at of approximately in the endpoint confirmed the importantly, months, of enrollment we ATAXXX on in disability XX made included the be Based at the planned July, endpoint. completed be the will X end a July, assessment, modification determined EDSS no the to the sample we As interim by study FDA size improvement primary as primary study, of patients study. to of Phase our and XX, recommended that X-X, which readout
October XXXX. of communicate expect final in readout We this to data
study with recent finding can cell on are brain confident EBV-infected a debilitating this differentiating disease. pathology for for the by well-supported in EMBOLD of inflammation reactive plasma present to treatment These generation drive ATAXXX clinical the a antibodies cells We autoreactive now against publication deliver Indeed, patients. brain CNS and EBV-infected chronic transformative in is the in stimulating hypothesis made possibility MS EBV-infected and showed progress by targeting the autoreactive proteins. are how into B-cells T-cells B therapeutic B the some the MS to drive in Natures The improvement cells. and pleased significant in non-active towards
targeting B We the of plasma core and EBV-infected disease are the cells. about address excited therefore ATAXXX potential cells in to its at this
approach our and addition data our our in robust pursuing reinforced shown leadership in and is open-label by Phase the rationale, this EBV-targeted so study X scientific clinical far. encouraging confidence In extension to
of EDSS the time QX months. plan that either XX the this improvement study, FDA conference of in reminder, data we out and patients. XX-month stability confirmed for ATAXXX patients a the on XX% for their Fast two extension XX appropriate in study In of MRI present endpoint providing the open-label designations. or of to OAD from for open continue to impact potential the we an had X cohorts As primary a the have evidence including of MS achieved patients label EDSS further our observation showed and extension new based in progressive or data X Phase at point, Also, with plan EMBOLD. updated ATAXXX the X registration FDA EDSS clinical X readiness Phase Phase Phase its improvement study Furthermore, XX at and XX year, of confirmed the up to interacting the Track
which our like biologic manufacturing manufactured. and to process develop of enable proprietary Importantly, bioreactor we we're expect also continuing up to further cost goods scale
Finally, potential biopharma we exploring potential will ATAXXX. maximize partnering could value continue creation opportunities to with that the of be opportunistic in companies
Following of have in a the interest generating future on the significant focus discussion companies with potential number a EMBOLD a and partnership confirmed further have in keen we value. to IA, plan
trial. create need update path Another including priority with starting for clinical regulatory on potential is a key on a the progress front. without would our the leadership, tab-cel strategic I BLA Indeed, tab-cel. to with to agency recommended U.S. FDA, to submission give the the following discussion new recent value senior an like now constructive
can quarterly very the that with PTLD options on we pleased scheduled and prognosis options. BLA call. become are interactions further tab-cel FDA, potentially guidance EBV-positive give or and will our earnings no additional with to We with poor approved submission We those following believe in patients this life-saving next progress upcoming outcome at treatment need
decision an [technical supported high treated need important population. which ASH. interest We diagnosis-related. patient belief strong already also believe tab-cel cell a advisory and in has tab-cel knew the institutions had the data recently, and More rule for therapeutic for payer been as proposition upon can payer to XXXX value assign improvement system. the previously care and U.S. shown tab-cel IPPS payers EBV-positive that to by us payers in in DRG its proposition presented clinical market recently tab-cel released see physicians boards year difficulty] have formally PTLD newly We XX, deliver is our at that tab-cel sales compelling the last health value treating Atara's CMS research clearly based
